ArticleBJUI compass2026
Oncological outcomes post focal low-dose-rate brachytherapy in low-intermediate risk prostate cancer.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oncological outcomes post focal low-dose-rate brachytherapy in low-intermediate risk prostate cancer.BJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To prospectively evaluate oncological control, pathological progression, and its predictors following focal low-dose-rate (LDR) brachytherapy for low-intermediate risk prostate cancer (PCa). Patients and methods: LIBERATE is a prospective, multi-centre clinical registry of patients who have undergone focal LDR brachytherapy for low-intermediate risk PCa since September 2019 (ACTRN:12619001669189). Unifocal ISUP GG1 (≥10 mm in ≥1 core), GG2 (any length) or GG3 (longest core<10 mm) were included. Follow-up entailed serial PSA measurements, and surveillance mpMRI and repeat transperineal prostate biopsy at 18-24 months post-treatment. Pathological control was achieved on repeat biopsy if there was no cancer or ISUP GG1 in <10 mm of core or GG2-3 grade cancer with radiation treatment effect. Progression was defined as no pathological changes from baseline or tumour upgrading. Results: Of 120 men enrolled, 55 (45.8%) have completed repeat histopathological assessments with a median (IQR) follow-up of 38 (33-45) months. Pathological control was reported in 42 (76.4%) patients, including 25 negative biopsies, 12 clinically insignificant disease, and five in-field ISUP GG2-3 with radiation treatment effect. Pathological progression was observed in 13 patients (23.6%), with concurrent clinically significant in- and out-of-field progression in three cases (5.5%) and isolated clinically significant out-of-field progression in 10 cases (18.2%). Five (9.1%) patients underwent salvage treatment, including three robotic-assisted radical prostatectomies, one contralateral lobe LDR brachytherapy and one external beam radiation therapy. The salvage-free survival at 1, 2, 3 and 4 years were 98.2%, 96.4%, 94.2% and 87.0%, respectively. Mean PSA velocity >0.55 ng/mL/year was a strong predictor of pathological progression (OR 23.54, 95% CI 4.28-129.35, Conclusion: With a median follow-up of 38 months, these early results suggest that focal LDR brachytherapy for low-intermediate risk, single-lesion, imaging-visible PCa demonstrates satisfactory oncological control. However, further follow-up is needed to assess long-term oncological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.